Another limitation that could potentially impact study results is the substantial heterogeneity of cancer types between patients treated with PD-1 versus PD-L1 inhibitors, as patients treated with PD-L1 inhibitors did mainly have NSCLC, whereas patients treated with PD-1 inhibitors had a greater variance of malignancies. This evidence concerns the gene CD274 and cancer.